EP2200591A2 - Pharmazeutische dosierungsformen von trimetazidin mit verzögerter freisetzung - Google Patents

Pharmazeutische dosierungsformen von trimetazidin mit verzögerter freisetzung

Info

Publication number
EP2200591A2
EP2200591A2 EP08807614A EP08807614A EP2200591A2 EP 2200591 A2 EP2200591 A2 EP 2200591A2 EP 08807614 A EP08807614 A EP 08807614A EP 08807614 A EP08807614 A EP 08807614A EP 2200591 A2 EP2200591 A2 EP 2200591A2
Authority
EP
European Patent Office
Prior art keywords
trimetazidine
dosage form
pharmaceutically acceptable
controlled release
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08807614A
Other languages
English (en)
French (fr)
Inventor
Sweta Varshney
Anant Ramesh Katkar
Kalaiselvan Ramaraju
Rajan Kumar Verma
Rajeev Singh Raghuvanshi
Himadri Sen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP2200591A2 publication Critical patent/EP2200591A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to new solid pharmaceutical dosage forms for the controlled release of trimetazidine suitable for once-daily dosing.
  • Trimetazidine [l-(2,3,4-trimethoxybenzyl piperazine] is a 3-ketoacyl-coenzyme A thiolase inhibitor with a cytoprotective effect, which by preserving the energy metabolisms of the cell exposed to the hypoxia or ischaemia, avoids the collapse of the intracellular rate of adenosine triphosphate (ATP). Thus it ensures the functioning of the ion pumps and the sodium-potassium transmembrane flux and maintains the cellular homeostasis.
  • ATP adenosine triphosphate
  • Trimetazidine dihydrochloride is used therapeutically in the long-term treatment of angina pectoris. It is freely soluble in water and has two pKa values 4.32 and 8.95. Trimetazidine dihydrochloride is administered orally in doses of 40 to 60mg daily in divided doses as an immediate release preparation. It is quickly absorbed and eliminated by the organism with plasma half-life of around 6.0 +/- 1.4 hours and Tmax of around 1.8 +/- 0.7 hours. Since it has a shorter plasma half life, in practice 20mg preparation is given twice or thrice a day in order to ensure relatively constant plasma levels. Servier had developed a modified-release dosage form containing 35mg for twice- daily administration, marketed under the brand name "VASTAREL MR".
  • This dosage form was bioequivalent to the 20 mg conventional thrice-a-day formulation of trimetazidine hydrochloride.
  • the modified-release formulation is based on a hydrophilic matrix that utilizes polymers which swell in contact with gastrointestinal fluids to form gels.
  • This formulation has been covered by Servier in a European patent published as EP 1 108 424, which discloses a matrix tablet enabling prolonged release of trimetazidine comprised of cellulose derivative polymers.
  • the formulation described releases more than 90% of the drug in-vitro within a period of 4 hours.
  • European patent EP 0 673 649 also assigned to Servier describes pharmaceutical compositions for the prolonged release of trimetazidine wherein prolonged release is ensured by the reservoir system.
  • the composition is prepared by compression of the active ingredient mixture and excipient, which are then coated with an insoluble polymer.
  • hydrophilic polymers for controlling the release of trimetazidine from the controlled release pharmaceutical compositions.
  • water-soluble salts such as hydrochloride salt of trimetazidine, it may result in burst release or dose dumping.
  • the PCT application WO 03/043610 filed by Themis Laboratories discloses a process for manufacturing microbeads, which enable "once a day” dosing for 60 mg dose of trimetazidine dihydrochloride per unit dose.
  • the application further provides dissolution rates at different time periods which correspond to 24 hours therapeutic blood levels. Further, it discloses the dissolution rate to be not less than 65% w/w in 6 hours.
  • the European patent application EP 1 195 160 filed by USV discloses a sustained release dosage form of trimetazidine that releases more than 90% of the drug in- vitro within a period of about 6 hours to about 8 hours.
  • the dosage form employs hydrophobic substance and a hydrocolloid for sustaining the release.
  • a controlled in vitro release of trimetazidine is of most importance in the context of in vivo drug profiles.
  • Drug absorption from a solid dosage form following oral administration depends on the release of the drug substance from the drug product, the dissolution or solubilization of the drug under physiological conditions, and the permeability across the gastrointestinal tract. Because of the critical nature of the first two of these steps, in vitro dissolution may be relevant to the prediction of in vivo performance.
  • trimetazidine taking into account the great therapeutic interest of trimetazidine, there exists a need in the state of the art for new pharmaceutical dosage forms for "once a day” dosing of trimetazidine, prepared by a simpler process that is cost-effective and yields a dosage form with pH independent release of trimetazidine for at least 16 hours without any lag period.
  • the present invention provides new solid pharmaceutical dosage forms for the controlled release of trimetazidine suitable for once-daily dosing, in which the dosage form exhibits a controlled in vitro release of trimetazidine in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours when measured using USP Apparatus I at 100 rpm, thereby decreasing the incidence and severity of burst release or dose dumping.
  • the pharmaceutical dosage form of the present invention uses a cost effective and rapid operation process.
  • water-insoluble polymers have been employed as a coating polymer in reservoir systems, these systems produced a release profile where trimetazidine hydrochloride is not available for immediate absorption and pharmacological action.
  • Other factors such as complexity of process, need for specialized equipment, incomplete release, etc. may also limit its use.
  • the present invention utilizes a simpler process of employing water-insoluble polymers as the matrix forming polymer.
  • the water insoluble polymers due to their nature, may result in a slower release, particularly in the beginning, leading to a lag phase. This is mainly due to less intake of aqueous medium.
  • a water swellable polymer may be incorporated in the matrix which results in increased early wetting.
  • a controlled release monolithic matrix dosage form comprising:
  • trimetazidine or its pharmaceutically acceptable salts
  • one or more rate controlling polymers selected from the group consisting of a water- insoluble polymer , water- swellable polymer, and mixture thereof, and
  • the dosage forms contain about 50 mg to about 80 mg of trimetazidine.
  • controlled release dosage forms of trimetazidine suitable for once-daily dosing contain about 70 mg of trimetazidine.
  • Controlled release dosage forms of the present invention comprise about 5 to 50% by weight of trimetazidine based upon the total weight of the dosage form.
  • water-insoluble rate controlling polymers include but are not limited to, one or more of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, co-polymers of acrylate or methacrylate having a low quaternary ammonium content, poly vinyl acetate, or mixtures thereof.
  • the water- insoluble polymers are ethyl cellulose, acrylic acid polymers or a combination of the two.
  • the water-insoluble polymers comprise about 5 to about 90% by weight of the dosage form.
  • the water-insoluble polymers may comprise about 20 to about 60% by weight of the dosage form.
  • water swellable rate controlling polymers include but are not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, methylcellulose, starch, gums, alginates, acrylic acid derivatives, gelatin and polyethylene oxide. Particularly the water swellable rate controlling polymer is xanthan gum.
  • the water swellable polymers may comprise about 5 to about 90% by weight of the dosage form. Particularly the water swellable polymers may comprise about 7% to about 60% by weight of the dosage form.
  • the highly water soluble drug trimetazidine or one of its salts is dispersed in a hydrophobic material.
  • a controlled release monolithic matrix dosage form of trimetazidine comprising:
  • rate controlling polymers selected from the group consisting of a water- insoluble polymer , water- swellable polymer, and mixture thereof, wherein trimetazidine is dispersed uniformly in the hydrophobic material, and wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • hydrophobic material examples include but are not limited to, one or more of fatty acids, long chain fatty alcohols, waxes, vegetable oil and glycerides of C ⁇ -Ci 8 fatty acids or mineral oil or mixtures thereof.
  • the hydrophobic material comprises carnauba wax, stearic acid or mixtures thereof.
  • the hydrophobic materials may comprise about 5 to about 90% by weight of the dosage form. Particularly the hydrophobic materials may comprise about 20 to about 60% by weight of the dosage form.
  • step (b) compressing the blend of step (a) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • step (b) blending/mixing the material of step (a) with one or more pharmaceutically acceptable excipients, and (c) compressing the blend of step (b) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • the granulation is carried out by wet granulating the active and the pharmaceutically acceptable excipients with a solution or dispersion of rate controlling polymer.
  • a part of the rate controlling polymer is added along with the active.
  • the granulation is carried out by dry blending the active, the pharmaceutically acceptable excipients and the rate controlling polymers and compacting to form granules.
  • a process for preparing a controlled release monolithic matrix dosage form of trimetazidine comprising the steps of: (a) dispersing trimetazidine in at least one hydrophobic material;
  • step (b) milling the material of step (a);
  • step (c) mixing/blending the material of step (b) with a rate controlling polymer and other excipients;
  • step (d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • step (a) dispersing trimetazidine in atleast one hydrophobic material; (b) milling the material of step (a);
  • step (c) granulating the material of step (b) with a rate controlling polymer and other excipients;
  • step (d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • the active is dispersed in at least one hydrophobic material with the help of solvents or by melting the hydrophobic material slightly above its melting point and dispersing the active in it.
  • the granulation is carried out by wet granulating the active and the pharmaceutically acceptable excipients with a solution or dispersion of rate controlling polymer.
  • a part of the rate controlling polymer is added along with the active.
  • the granulation is carried out by dry blending the active, the pharmaceutically acceptable excipients and the rate controlling polymers and compacting to form granules.
  • Example of solvents used for granulation comprise methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water or mixtures thereof.
  • the hydrophobic materials were melted at temperatures ranging from about 4O 0 C to about 120° C. Particularly, the hydrophobic materials were melted at a temperature range of about 60° C to about 80° C.
  • the controlled release dosage forms comprise one or more pharmaceutically acceptable excipients selected from one or more of binders, fillers, lubricants, glidants, coloring agents and flavoring agents.
  • the dosage form is optionally coated with one or more layers comprising film forming agents and/or pharmaceutically acceptable excipients.
  • a method of prophylactic treatment of angina pectoris comprising administering a controlled release monolithic matrix dosage form of trimetazidine, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • the controlled release monolithic matrix dosage form of trimetazidine may be administered in combination with other cardio therapeutic agents.
  • the details of one or more embodiments of the inventions are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and claims.
  • the present invention relates to controlled release dosage forms of trimetazidine suitable for once-daily dosing, containing less than about lOOmg of trimetazidine.
  • the dosage forms Preferably contain about 50 mg to about 80 mg of trimetazidine.
  • controlled release dosage forms of trimetazidine suitable for once-daily dosing contain about 70mg of trimetazidine.
  • Trimetazidine used herein should be understood as the base or any of its pharmaceutically acceptable salt thereof. Particularly, the salt is dihydrochloride. Controlled release dosage forms of the present invention comprise about 5 to 50% by weight of trimetazidine.
  • controlled-release includes any type of controlled- release including prolonged release, sustained release, modified release and extended release.
  • the pharmaceutical dosage forms of the present invention can be administered orally in the form of tablets or capsules filled with pellets, beads, granules, multiparticulates, tablets or powder.
  • the present invention employs water insoluble polymeric matrix to control the release of highly water soluble trimetazidine.
  • a water swellable polymer is also added to the matrix to allow the aqueous medium to penetrate the dosage form and provide a tortuous path for uniform drug release.
  • the active is released uniformly over a period of 12 to 24 hours in a substantially linear or zero order release.
  • water-insoluble rate controlling polymers include but are not limited to, one or more of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, co-polymers of acrylate or methacrylate having a low quaternary ammonium content, poly vinyl acetate, or mixtures thereof.
  • the water- insoluble polymers are ethyl cellulose, acrylic acid polymers or a combination of the two.
  • the water-insoluble polymers comprise about 5 to about 90% by weight of the dosage form.
  • the water-insoluble polymers may comprise about 20 to about 60% by weight of the dosage form.
  • water swellable rate controlling polymers include but are not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, methylcellulose, starch, gums, alginates, acrylic acid derivatives, gelatin and polyethylene oxide.
  • the water swellable polymers may comprise about 5 to about 90% by weight of the dosage form. Particularly the water swellable polymers may comprise about 7% to about 60% by weight of the dosage form.
  • trimetazidine from the dosage form is further controlled in the early phase and a near zero-order release profile is obtained when the drug is dispersed in a hydrophobic material.
  • hydrophobic material examples include but are not limited to, one or more of fatty acids, long chain fatty alcohols, waxes, vegetable oil and glycerides of C ⁇ -Ci 8 fatty acids or mineral oil or mixtures thereof.
  • the hydrophobic materials may comprise about 5 to about 90% by weight of the dosage form. Particularly the hydrophobic materials may comprise about 20 to about 60% by weight of the dosage form.
  • the controlled release dosage forms may further comprise one or more pharmaceutically acceptable excipients.
  • the pharmaceutically acceptable excipients are those known to the skilled in the art and may be selected from binders, fillers, lubricants, glidants, coloring agents and flavoring agents.
  • binders include, but are not limited to, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, pregelatinized starch, agar, tragacanth, sodium alginate and propylene glycol.
  • fillers or diluents include, but are not limited to, corn starch, lactose, white sugar, sucrose, sugar compressible, sugar confectioners, glucose, sorbitol, calcium carbonate, calcium dihydrogen phosphate dihydrates, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, starch and starch pregelatinized.
  • the fillers comprise microcrystalline cellulose, calcium dihydrogen phosphate dihydrate or a mixture of both.
  • lubricants and glidants include, but are not limited to, colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax and white beeswax.
  • the coloring agents and flavoring agents of the present invention may be selected from any FDA approved colors and flavors for oral use.
  • the ingredients discussed above may be formed into dosage forms by conventional techniques, for example either by direct compression, or first compacting some of the ingredients, milling the compacts, blending with the remaining ingredients and then compressing as appropriate.
  • the controlled release monolithic matrix dosage forms may also be prepared using wet granulation techniques.
  • the process may include granulation of trimetazidine and the rate controlling polymers with a solvent or granulation of trimetazidine with a solution of the polymer.
  • the process may further include drying the granules prior to compressing into tablets.
  • controlled release dosage forms of the present invention can optionally be coated with one or more layers comprising film forming agents and/or pharmaceutically acceptable excipients.
  • Coating may be performed by applying one or more film forming polymers with or without other pharmaceutically inert excipients. This may be done as a solution or suspensions using any conventional coating technique known in the prior art, such as spray coating in a conventional coating pan or fluidized bed processor, or dip coating.
  • Suitable film forming polymers include one or more of ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, waxes, methacrylic acid polymers such as Eudragit® RL and RS, and mixtures thereof.
  • the coating can also be performed using any commercially available ready to coat preparations such as Opadry-AMB, Opadry- White, Opadry-Clear, etc.
  • Suitable solvents used for making a solution/suspension of film forming polymer include one or more of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.
  • a controlled release monolithic matrix dosage form of trimetazidine in the prophylactic treatment of angina pectoris wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • the controlled release monolithic matrix dosage form of trimetazidine may be administered in combination with other cardio therapeutic agents.
  • Trimetazidine dihydrochloride, microcrystalline cellulose (High viscosity), xanthan gum & ethylcellulose (High viscosity) were mixed and granulated with ethylcellulose (Low viscosity).
  • step-1 Granules of step-1 were blended with microcrystalline cellulose (Low viscosity), carbopol, colloidal silicon dioxide and magnesium stearate.
  • the controlled release (CR) dosage forms prepared according to Examples 1, 2 and 3 were subjected to in vitro drug release test which utilizes the United States Pharmacopea (USP) Apparatus 1 (rotating basket) at 100 rpm with 500 ml of phosphate buffer at pH 6.8 and 37° C.
  • USP United States Pharmacopea
  • the results of the in vitro drug release test are given in Table 1.
  • Table 1 Drug Release of Trimetazidine CR dosage forms prepared as per Examples 1, 2 and 3 in Phosphate buffer pH 6.8, 500 ml, USP 1 at 100 rpm.
  • Example 4 Controlled release monolithic matrix dosage form of trimetazdine dihydrochloride
  • Trimetazidine hydrochloride was dispersed in a molten mass of carnauba wax and stearic acid.
  • step 1 Dispersion of step 1 was stirred till it cooled.
  • step 2 Material of step 2 was milled and blended with ethyl cellulose; xanthan gum; microcrystalline cellulose; colloidal silicon dioxide and magnesium stearate.
  • Trimetazidine hydrochloride was dispersed in a molten mass of carnauba wax and stearic acid.
  • step 1 Dispersion of step 1 was stirred till it cooled. 3.
  • Material of step 2 was milled and blended with ethyl cellulose; xanthan gum; microcrystalline cellulose; calcium dihydrogen phosphate dihydrate; colloidal silicon dioxide and magnesium stearate.
  • step 3 Material of step 3 was compressed into tablets.
  • step 4 Tablets of step 4 were coated with the coating composition.
  • the controlled release (CR) dosage form prepared according to Example 5 were subjected to in vitro drug release test which utilizes the United States Pharmacopea (USP) Apparatus 1 (rotating basket) at 100 rpm with 500 ml of phosphate buffer at pH 6.8 and 37° C.
  • USP United States Pharmacopea
  • the results of the in vitro drug release test are given in Table 2.
  • Table 2 Drug Release of Trimetazidine CR dosage form prepared as per Example 5 in Phosphate buffer pH 6.8, 500 ml, USP 1 at 100 rpm.
  • Table 3 Pharmacokinetic data for controlled release (CR) monolithic matrix dosage forms prepared as per present invention. Once daily vs. three doses of VASTAREL 20 mg tablets (containing trimetazidine 20 mg) administered thrice daily
  • Table 4 Pharmacokinetic data for controlled release controlled release monolithic matrix dosage forms prepared as per present invention. Once daily vs. two doses of VASTAREL MR 35 mg tablets (containing trimetazidine 35 mg) administered twice daily

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP08807614A 2007-09-11 2008-09-11 Pharmazeutische dosierungsformen von trimetazidin mit verzögerter freisetzung Withdrawn EP2200591A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1925DE2007 2007-09-11
IN1226DE2008 2008-05-16
PCT/IB2008/053679 WO2009034541A2 (en) 2007-09-11 2008-09-11 Controlled release pharmaceutical dosage forms of trimetazidine

Publications (1)

Publication Number Publication Date
EP2200591A2 true EP2200591A2 (de) 2010-06-30

Family

ID=40120263

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08807614A Withdrawn EP2200591A2 (de) 2007-09-11 2008-09-11 Pharmazeutische dosierungsformen von trimetazidin mit verzögerter freisetzung

Country Status (2)

Country Link
EP (1) EP2200591A2 (de)
WO (1) WO2009034541A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
TR201001902A2 (tr) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salınımlı trimetazidin tablet
US20110274751A1 (en) * 2010-05-04 2011-11-10 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Trimetazidine formulation with different release profiles
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102824644B (zh) * 2012-09-13 2013-12-25 浙江诚意药业有限公司 使用羟丙基纤维素制备的高稳定性的缓释片
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (de) * 2014-05-26 2017-04-05 Grünenthal GmbH Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP4378457A3 (de) 2016-11-21 2024-07-31 Saghmos Therapeutics, Inc. Prävention und/oder behandlung von kontrastinduzierter akuter nierenverletzung
US20180190374A1 (en) * 2017-01-03 2018-07-05 Saghmos Therapeutics, Inc. Methods of improving patient compliance to treat contrast-induced injury
CN109908096A (zh) * 2017-12-12 2019-06-21 武汉武药科技有限公司 一种盐酸曲美他嗪缓释片及其制备方法
CN110623934B (zh) * 2019-09-26 2022-05-13 杭州百诚医药科技股份有限公司 一种盐酸曲美他嗪缓释片及其制备方法
CN111888476A (zh) * 2020-08-17 2020-11-06 深圳市道科思医药有限公司 盐酸曲美他嗪的改良释放药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0625055B2 (ja) * 1985-03-18 1994-04-06 日本ケミフア株式会社 持続性錠剤
FR2717687B1 (fr) * 1994-03-24 1996-06-14 Adir Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
DE60042972D1 (de) 2000-10-05 2009-10-29 Usv Ltd Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
FR2818549B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controlee de trimetazidine
EP1448173A2 (de) 2001-11-21 2004-08-25 Themis Laboratories Private Limited Verfahren zur herstellung einer zusammensetzung mit verzogerter wirkstoffabgabe enthaltend trimetazidinhydrochlorid-mikrospheren
FR2885807B1 (fr) * 2005-05-18 2008-05-16 Mg Pharma Composition pharmaceutique solide a liberation prolongee de 1-(2,3,4-trimethoxybenzyl) piperazine, et procede de preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009034541A2 *

Also Published As

Publication number Publication date
WO2009034541A2 (en) 2009-03-19
WO2009034541A9 (en) 2009-12-30
WO2009034541A3 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
EP2200591A2 (de) Pharmazeutische dosierungsformen von trimetazidin mit verzögerter freisetzung
US11679105B1 (en) Pharmaceutical compositions of cabozantinib
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
EP2448561B1 (de) Feste pharmazeutische zusammensetzungen in fixer dosisform mit irbesartan und amlodipin, ihre zubereitung und therapeutische anwendung
JPH061716A (ja) 活性成分の長期放出性を有する投薬形
WO2010128525A2 (en) A formulation of ivabradine for treating the cardiovascular disease
US20140050784A1 (en) Pharmaceutical compositions of memantine
EP2603207A2 (de) Pharmazeutische orale retard-zusammensetzungen aus blonanserin
US20230012071A1 (en) Modified release pharmaceutical compositions of riociguat
WO2022144919A1 (en) Extended release pharmaceutical compositions of riociguat
KR20180097623A (ko) 아프레밀라스트 서방형 제제
BR112014020184B1 (pt) Preparação farmacêutica que contém anlodipina e ra-mipril
FI100303B (fi) Menetelmä suun kautta annettavan buspironin ja sen suolan valmistamise ksi
WO2020109319A1 (en) Pharmaceutical composition comprising ramipril and indapamide
EP3331502B1 (de) Propiverin-formulierungen mit kontrollierter freisetzung
EP4079297A1 (de) Pharmazeutische formulierung mit cibenzolin oder salz davon
EP3796908B1 (de) Propiverin-formulierungen mit kontrollierter freisetzung
CN101090738A (zh) 含有碱性药物或其盐的基质型缓释制剂及其制备方法
KR101093781B1 (ko) ｐＨ조절제를 함유하는 목시플록사신 고형 조성물
WO2008068778A2 (en) Extended release pharmaceutical composition of pramipexole
WO2005034948A1 (en) Solid dosage formulation containing a factor xa inhibitor and method
US8512746B2 (en) Extended release pharmaceutical compositions of levetiracetam
JP4696210B2 (ja) イソソルビド‐５‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
JP2021518424A (ja) 様々な用量のレナリドミドの経口用錠剤組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100412

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20110713

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111124